

by FRT-Flp recombinase mediated integration.

A cell line can be stably transformed with both the pFRT/lacZeo (already in the parental Flp-in Jurkat cell line) and the pcDNA6/TR plasmids. A gene of interest is cloned into plasmid, pcDNA5/FRT/TO. When pcDNA5/FRT/TO, including the gene of interest, is co-transfected along with a plasmid supplying a source of Flp recombinase into the cell line, the recombinase mediates the insertion of the gene of interest into the Flp recombination target (FRT) site in the pFRT/lacZeo plasmid that becomes integrated into the DNA of the cell line. The gene of interest can then be expressed in a tetracycline inducible fashion.

#### Method of Assessing Ischemia in a Patient

Steven Warach and Lawrence Latour (NINDS).

DHHS Reference No. E-082-2002 Filed Mar. 17, 2002.

*Licensing Contact:* Michael Shmilovich; 301/435-5019; [mish@codon.nih.gov](mailto:mish@codon.nih.gov).

Hyperintense acute reperfusion marker (HARM) is well correlated with reperfusion and is a precursor to or concomitant with reperfusion injury and hemorrhagic transformation. The inventors have developed a novel technique of assessing early blood brain barrier disruption associated with ischemic stroke in a patient by administering a contrast agent to the patient, acquiring a fluid-attenuated inversion-recovery (FLAIR) image, and observing the presence or absence of HARM on the acquired image. The technique can also be used to determine the effectiveness of a therapeutic protocol for the treatment or prevention of reperfusion injury or hemorrhagic transformation in a patient that has suffered an ischemic event.

Dated: May 9, 2003.

#### Steven M. Ferguson,

*Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 03-12278 Filed 5-15-03; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Fogarty International Center; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the Fogarty International Center Advisory Board.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Fogarty International Center Advisory Board.

*Date:* May 20, 2003.

*Closed:* 9 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892.

*Open:* 11 a.m. to 12 p.m.

*Agenda:* A Report of the FIC Director on updates and overviews of new FIC initiatives.

*Place:* National Institutes of Health, Lawton Chiles International House, Bethesda, MD 20892.

*Contact Person:* Irene W. Edwards, Information Officer, Fogarty International Center, National Institutes of Health, Building 31, Room B2C08, 31 Center Drive MSC 2220, Bethesda, MD 20892, 301-496-2075.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Information is also available on the Institute's/Center's home page: <http://www.nih.gov/fic/about/advisory.html> where an agenda and any additional information for the meeting will be posed when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.106, Minority International Research Training Grant in the Biomedical and Behavioral Sciences; 93.154, Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome; 93.168, International Cooperative Biodiversity Groups Program; 93.934, Fogarty International Research Collaboration Award; 93.989, Senior International Fellowship Awards Program, National Institutes of Health, HHS)

Dated: May 12, 2003.

#### LaVerne Y. Stringfield,

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 03-12274 Filed 5-15-03; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Human Genome Research.

*Date:* May 19, 2003.

*Open:* 8:30 a.m. to 12:30 p.m.

*Agenda:* To discuss matters of program relevance.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Closed:* 1:30 p.m. to adjournment at 5 p.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892.

*Contact Person:* Mark S. Guyer, Director for Extramural Research, Assistant Director for Scientific Coordination, National Human Genome Research Institute, 31 Center Drive, MSC 2033, Building 31, Room B2B07, Bethesda, MD 20892-2033, 301-435-5536, [guyerm@mail.nih.gov](mailto:guyerm@mail.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.